Linagliptin Stada Arzneimittel Ag

Linagliptin, the active ingredient in Linagliptin Stada Arzneimittel Ag, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults.

GNH USA supplies Linagliptin Stada Arzneimittel Ag as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linagliptin is a DPP‑4 inhibitor used in the treatment of type 2 diabetes mellitus, helping to improve glycaemic control when combined with diet and exercise.

- Type 2 diabetes mellitus: improves blood glucose levels by enhancing insulin secretion and reducing glucagon release.

Linagliptin may cause a range of adverse reactions, some of which are more frequently reported than others.

Common Side Effects: - Nasopharyngitis: mild inflammation of the nasal passages and throat. - Headache: transient head discomfort of varying intensity. - Upper respiratory tract infection: symptoms such as cough, sore throat, or congestion. - Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain that may indicate inflammation of the pancreas. - Severe allergic reactions: including rash, angioedema, or anaphylaxis. - Hepatic injury: abnormal liver function tests or jaundice. - Bullous pemphigoid: rare skin disorder characterized by blistering lesions.

Before initiating linagliptin therapy, certain precautions should be considered to ensure safe use.

- Renal function monitoring: assess kidney status, especially in patients with impairment. - Hepatic function monitoring: evaluate liver enzymes periodically. - Cardiovascular risk assessment: consider in patients with existing heart disease. - Use with caution in the elderly: increased susceptibility to adverse events. - Avoid in patients with known hypersensitivity to linagliptin or excipients. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Linagliptin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce linagliptin effectiveness. - Insulin secretagogues (e.g., sulfonylureas): heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: possible alterations in fluid balance affecting glucose control. - Antihypertensive agents: monitor blood pressure as glycaemic changes may occur. - Other antidiabetic drugs: assess for additive glucose‑lowering effects.